Cutler Group’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $29K | Hold |
4,200
| – | – | 0.01% | 877 |
|
|
2023
Q4 | $20K | Buy |
+4,200
| New | +$372K | ﹤0.01% | 1968 |
|
|
2022
Q4 | – | Sell |
-1,400
| Closed | -$5K | – | 4421 |
|
|
2022
Q3 | $5K | Sell |
1,400
-1,100
| -44% | -$97.9K | ﹤0.01% | 3615 |
|
|
2022
Q2 | $7K | Sell |
2,500
-1,600
| -39% | -$127K | ﹤0.01% | 3433 |
|
|
2022
Q1 | $17K | Buy |
4,100
+100
| +3% | +$8.37K | ﹤0.01% | 3176 |
|
|
2021
Q4 | $6K | Buy |
+4,000
| New | +$330K | ﹤0.01% | 4032 |
|
|
2021
Q3 | – | Sell |
-1,200
| Closed | -$5K | – | 5717 |
|
|
2021
Q2 | $5K | Buy |
+1,200
| New | +$95.1K | ﹤0.01% | 4400 |
|
|
2021
Q1 | – | Sell |
-21,800
| Closed | -$8K | – | 5640 |
|
|
2020
Q4 | $8K | Buy |
21,800
+18,900
| +652% | +$1.5M | ﹤0.01% | 3320 |
|
|
2020
Q3 | $8K | Buy |
+2,900
| New | +$293K | ﹤0.01% | 3127 |
|
|
2020
Q2 | – | Sell |
-4,500
| Closed | -$25K | – | 4390 |
|
|
2020
Q1 | $25K | Sell |
4,500
-2,500
| -36% | -$215K | ﹤0.01% | 2150 |
|
|
2019
Q4 | $24K | Buy |
+7,000
| New | +$529K | ﹤0.01% | 2101 |
|
|
2019
Q3 | – | Sell |
-7,500
| Closed | -$17K | – | 4087 |
|
|
2019
Q2 | $17K | Buy |
7,500
+4,500
| +150% | +$385K | ﹤0.01% | 2312 |
|
|
2019
Q1 | $21K | Sell |
3,000
-39,100
| -93% | -$3.62M | ﹤0.01% | 2007 |
|
|
2018
Q4 | $295K | Buy |
42,100
+31,200
| +286% | +$2.97M | 0.03% | 488 |
|
|
2018
Q3 | $26K | Buy |
10,900
+3,100
| +40% | +$309K | ﹤0.01% | 2070 |
|
|
2018
Q2 | $24K | Sell |
7,800
-2,300
| -23% | -$201K | ﹤0.01% | 2062 |
|
|
2018
Q1 | $38K | Sell |
10,100
-25,800
| -72% | -$2.21M | ﹤0.01% | 1849 |
|
|
2017
Q4 | $80K | Buy |
35,900
+5,400
| +18% | +$470K | ﹤0.01% | 1521 |
|
|
2017
Q3 | $87K | Sell |
30,500
-19,100
| -39% | -$1.69M | ﹤0.01% | 1779 |
|
|
2017
Q2 | $209K | Sell |
49,600
-104,300
| -68% | -$9.49M | 0.01% | 1238 |
|
|
2017
Q1 | $422K | Buy |
153,900
+57,500
| +60% | +$5.12M | 0.02% | 722 |
|
|
2016
Q4 | $235K | Sell |
96,400
-14,400
| -13% | -$1.24M | 0.01% | 1182 |
|
|
2016
Q3 | $279K | Buy |
110,800
+47,200
| +74% | +$4.44M | 0.01% | 962 |
|
|
2016
Q2 | $277K | Buy |
63,600
+8,100
| +15% | +$689K | 0.01% | 905 |
|
|
2016
Q1 | $311K | Sell |
55,500
-500
| -0.9% | -$40.7K | 0.02% | 745 |
|
|
2015
Q4 | $368K | Buy |
+56,000
| New | +$5.85M | 0.02% | 787 |
|
Other funds holding BMRN
Cutler Group's BMRN Position: Q3 2023 in Review
Cutler Group sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 800 shares — an estimated $69K sold.
Cutler Group first reported a position in BMRN in Q4 2015 and held it in 27 quarters. The position peaked at $2.76M in Q3 2016. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.
- Cutler Group reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
- Cutler Group sold 800 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $69K.
- Cutler Group first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 27 quarters.
- Cutler Group's BioMarin Pharmaceuticals position peaked at $2.76M in Q3 2016.
- 519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.
Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.